Navigation Links
Comprendia and New England Biolabs Connect Epigenetics Scientists with New Social Media Application
Date:7/12/2011

SAN DIEGO and IPSWICH, Mass., July 12, 2011 /PRNewswire/ -- Comprendia, leading developer of web 2.0 and social media tools for the life sciences, sponsored by molecular biology reagents provider New England Biolabs, Inc. (NEB), is introducing an online resource that will support epigenetics research. Epigenetics is a quickly growing field with important implications for oncology, neurology, metabolism and disease mechanisms.  'Engaging Epigenetics Experts' (E3) is an online community that will allow epigenetics researchers to more easily connect so they can leverage their collective, interdisciplinary knowledge in a way that has not been possible before.

(Logo: http://photos.prnewswire.com/prnh/20110712/NE33845LOGO  )

E3 takes concepts that have popularized social media applications, like Facebook, to another level by utilizing research publications to connect epigenetics scientists. For example, E3 members can find a report about an interesting experiment and quickly engage with the author, saving valuable time and simplifying knowledge transfer. Traditionally, life science discussions have occurred through private email, one-on-one, local interactions, or at yearly conferences; the E3 interface facilitates these communications potentially in real time, and opens them up to the wider community through public forums.

Mary Canady, President of Comprendia said "We interviewed epigenetics researchers and learned that their most important need was more access to expertise with a technique or another discipline. E3 was designed to meet this need, using web 2.0 technologies, which allow them to interact more seamlessly than ever before."

The E3 application already contains 27,000 epigenetics publications from more than 1,000 researchers, as well as a list of experts curated from these publications. Scientists can search the publications by title, abstract, author, keyword or location, and then connect directly with authors in the E3 community. An online forum and blog will also help epigenetics researchers to connect and learn from each other. Groups and events can also be organized from within E3.

Tanya Bhatia, eMarketing Manager at New England Biolabs states "For over 35 years, NEB has been closely involved in supporting molecular biology research, and welcomes E3 as a natural next step in empowering researchers to be more productive. We also look forward to developing collaborations with E3 experts, and accelerating their research with NEB's EpiMark suite of products for epigenetics."

For more information about E3, visit www.epiexperts.com.

About Comprendia, LLC

Comprendia, LLC is dedicated to the marketing and social media needs of life science companies, helping them to meet their goals through strategic and tactical marketing solutions. Comprendia Social Media Charters help companies plan and execute strategies aimed at engaging and empowering scientific researchers through new media such as Facebook, Twitter, blogs, and web 2.0. Comprendia also serves as a life science liaison by hosting networking events, seminars, and workshops aimed at improving communication in the biotech industry.  

About New England Biolabs

Established in the mid 1970's, New England Biolabs, Inc. is the industry leader in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, gene expression, sample preparation for next generation sequencing, cellular analysis, epigenetics and RNA analysis. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key market sectors. New England Biolabs is a privately held company, headquartered in Ipswich, MA and has extensive worldwide distribution through a network of exclusive distributors, agents and five subsidiaries located in Canada, China, Germany, Japan and the UK. For more information about New England Biolabs visit www.neb.com.


'/>"/>
SOURCE New England Biolabs
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. New England Peptide Names Director of Chemical Development
2. NeoStem Secures $250,000 in an Above Market Financing and Expands Its Relationship With New England Cryogenic Center, Inc.
3. New England Peptide Forms Scientific Advisory Board
4. Gene Therapy Field Advances With Important Clinical Findings Reported in the New England Journal of Medicine
5. New England Journal of Medicine Study Highlights Need for Rapid, PCR-based Group B Streptococcus (GBS) Testing at Time of Admission for Labor and Delivery
6. Data Published in The New England Journal of Medicine Support Use of Raxibacumab (ABthrax(TM)) for the Treatment of Inhalation Anthrax
7. First U.K. Stem Cell Awareness Rally to Take Place in Manchester, England on August 9th, 2009
8. Ontario Institute for Cancer Research Validates NEBNext(TM) DNA Sample Preparation Reagents from New England Biolabs for use in Next Generation Sequencing
9. Wellcome Trust Sanger Institute to use NEBNext(TM) DNA Sample Preparation Reagents from New England Biolabs for Next Generation Sequencing
10. Organogenesis CEO Geoff MacKay and COO / CFO Gary Gillheeney Named Ernst & Young Entrepreneur Of The Year(R) 2009 Award Winners in New England
11. New England Biolabs Launches NEBNext(TM) DNA Sample Prep Master Mix Set 3 for Use with SOLiD(TM) 3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... 23, 2016  The Biodesign Challenge (BDC), a university ... to harness living systems and biotechnology, announced its winning ... New York City . ... showcased projects at MoMA,s Celeste Bartos Theater during the ... MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® Inc. (RCA), ... free webinar on Performing Quality Investigations: Getting to Root Cause. ... no charge. , Incomplete investigations are still a major concern to the Regulatory ...
Breaking Biology Technology:
(Date:6/1/2016)... , June 1, 2016 ... in Election Administration and Criminal Identification to Boost Global ... a recently released TechSci Research report, " Global Biometrics ... Region, Competition Forecast and Opportunities, 2011 - 2021", the ... billion by 2021, on account of growing security concerns ...
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour ... from the Q1 wave of its quarterly wearables survey. ... receptivity to a program where they would receive discounts ... company. "We were surprised to see that ... LaColla , CEO of Troubadour Research, "primarily because there ...
Breaking Biology News(10 mins):